GSK 2245035 PROBABLEMarch 19, 2015 4:12 am
GSK 2245035 PROBABLE8H-Purin-8-one, 6-amino-2-butoxy-7,9-dihydro-9-[[1-(2-hydroxyethyl)-4-piperidinyl]methyl]-
CAS NO 1264370-20-8
PHASE 2, Allergic asthma; Allergic rhinitis
Toll-like receptor 7 agonist
Immunomodulators; Interferon alfa 2a stimulants; Toll-like receptor 7 agonists
Patent
https://www.google.com/patents/WO2011098451A1?cl=en
Example 2: 6-Amino-2-(butyloxy)-9-([1 -(2-hvdroxyethyl)-3-piperidinyllmethyl|-7,9-dihydro-8/-/-purin-8- one
2-(Butyloxy)-8-(methyloxy)-9-(-piperidinylmethyl)-9/-/-purin-6-amine (for example, as prepared for Intermediate 14) (33.4 mg, 0.1 mmol) was suspended in DMF (0.3 mL) was added to 2- bromoethanol (commercially available, for example, from Aldrich) (0.0071 mL, 0.100 mmol). DIPEA (0.040 mL, 0.23 mmol) was added. The reaction was shaken in a stoppered vial at ambient temperature overnight. The reaction mixture was diluted with DMSO (0.4 mL) and the resultant solution purified by MDAP (Method A). Appropriate fractions were combined and evaporated in vacuo. The residues was dissolved in 4M HCI in dioxane (0.4 mL) and allowed to stand at room temperature overnight. The solvent was dried under a stream of nitrogen in the Radleys blowdown apparatus. The residue was redissolved in methanol (0.5 mL) and applied to the top of a 0.5 g aminopropyl SPE (preconditioned with methanol, 2 CV). The cartridge was washed with methanol (2 mL). The solvent was dried under a stream of nitrogen in the Radleys blowdown apparatus to give the title compound (0.022 g).
LCMS (System A): tRET = 0.57min; MH+ 365
REF
titis B vaccine both manufactured by GlaxoSmithKline. MPL is a nontoxic derivate … GSK2245035 compound that is a highly selective TLR7 agonist. Intranasal …
Posted by DR ANTHONY MELVIN CRASTO Ph.D
Categories: Phase2 drugs
Tags: gsk, GSK 2245035, phase 2
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.
